All > Stem Cell Transplant > High Blood Pressure

Total Body Irradiation for Pulmonary Hypertension

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Pulmonary Hypertension+3 MoreTotal Body Irradiation - Radiation
Eligibility
8 - 60
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new immunotherapy treatment for scleroderma, to see if it is safe and more effective than other treatments.

Eligible Conditions
  • Pulmonary Hypertension
  • Diffuse Systemic Sclerosis
  • Interstitial Lung Disease
  • Progressive Systemic Sclerosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
TEPEZZA
1
RO7303509
1
autologous CD34-selected peripheral blood stem cells transplant

Study Objectives

7 Primary · 6 Secondary · Reporting Duration: Disease response will be defined as subject improvement. This will be assessed for both skin and interstitial lung disease at 12 and 24 months post-HSCT.

Year 1
Decrease in DLCO sustained for 3 months or longer on pulmonary function tests (PFT)
Worsening of > 10% of FVC (pulmonary function testing)
Month 24
An increase of mRSS (modified Rodnan skin score ) by ≥5 points for skin score
Increase by ≥25% if the baseline mRSS > 20.
Month 36
Treatment-related mortality (TRM)
Month 36
Death
Development of scleroderma renal crisis (hypertensive or non-hypertensive)
Renal Failure
Respiratory Failure
The occurrence of cardiomyopathy
Worsening of cardiac involvement
Month 36
High Dose Immunoablative therapy-Safety
Month 36
High Dose Immunoablative therapy-Treatment Effect

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
TEPEZZA
1
RO7303509
1
autologous CD34-selected peripheral blood stem cells transplant

Side Effects for

Palifermin 180 μg/kg on Day -3 (D)
58%Diarrhoea
50%Nausea
50%Vomiting
42%Fatigue
42%Cough
33%Constipation
33%Oedema
33%Anorexia
33%Rash
17%Folliculitis
17%Dyspepsia
17%Headache
17%Asthenia
17%Bacteraemia
17%Neuropathy
17%Dizziness
17%Anxiety
17%Depression
17%Confusional state
17%Insomnia
17%Haematuria
17%Pruritus
17%Flushing
8%Hypertension
8%Engraftment syndrome
8%Febrile neutropenia
8%Hyperbilirubinaemia
8%Atrial fibrillation
8%Dysgeusia
8%Eye pruritus
8%Photophobia
8%Eye swelling
8%Abdominal pain
8%Pyrexia
8%Oesophagitis
8%Haematochezia
8%Tongue coated
8%Tongue disorder
8%Tongue geographic
8%Face oedema
8%Chills
8%Axillary pain
8%Chest discomfort
8%Oedema peripheral
8%Localised oedema
8%Feeling jittery
8%Agitation
8%Non-cardiac chest pain
8%Migraine
8%Peripheral sensory neuropathy
8%Syncope
8%Herpes simplex
8%Staphylococcal bacteraemia
8%Skin laceration
8%Upper respiratory tract infection
8%Delayed engraftment
8%Alanine aminotransferase increased
8%Aspartate aminotransferase increased
8%Transfusion reaction
8%Weight decreased
8%Intraocular pressure increased
8%Bone pain
8%Arthralgia
8%Chest wall pain
8%Joint stiffness
8%Mental disorder
8%Pollakiuria
8%Urinary retention
8%Dysuria
8%Prostatitis
8%Epistaxis
8%Dyspnoea
8%Hiccups
8%Lung infiltration
8%Dermatitis acneiform
8%Dermatitis allergic
8%Erythema
8%Drug eruption
8%Palmar-plantar erythrodysaesthesia syndrome
8%Petechiae
8%Rash erythematous
8%Hypotension
8%Jugular vein thrombosis
8%Orthostatic hypotension
This histogram enumerates side effects from a completed 2010 Phase 3 trial (NCT00109031) in the Palifermin 180 μg/kg on Day -3 (D) ARM group. Side effects include: Diarrhoea with 58%, Nausea with 50%, Vomiting with 50%, Fatigue with 42%, Cough with 42%.

Trial Design

1 Treatment Group

Autologous Stem Cell Transplantation
1 of 1

Experimental Treatment

8 Total Participants · 1 Treatment Group

Primary Treatment: Total Body Irradiation · No Placebo Group · Phase 2

Autologous Stem Cell TransplantationExperimental Group · 9 Interventions: Rituximab, Anti Thymocyte Globulin, GM-CSF, Thiotepa, Alemtuzumab, Intravenous immunoglobulin, Total Body Irradiation, Cyclophosphamide, Mesna · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug, Radiation, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved
Anti Thymocyte Globulin
2009
Completed Phase 4
~120
Filgrastim
FDA approved
Thiotepa
FDA approved
Alemtuzumab
FDA approved
Human immunoglobulin G
FDA approved
Total Body Irradiation
2006
Completed Phase 3
~890
Cyclophosphamide
FDA approved
Coenzyme M
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: disease response will be defined as subject improvement. this will be assessed for both skin and interstitial lung disease at 12 and 24 months post-hsct.

Who is running the clinical trial?

Paul SzabolcsLead Sponsor
6 Previous Clinical Trials
199 Total Patients Enrolled
Paul Szabolcs, MDPrincipal Investigator - University of Pittsburgh
University of Pittsburgh
6 Previous Clinical Trials
196 Total Patients Enrolled

Eligibility Criteria

Age 8 - 60 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Individuals must meet all the following criteria to be eligible for this study.
You must have given informed consent for this procedure.
You are aged 8-24 years at the time of consent.
You have skin thickening over the past 6 months or mRSS ≥ 20.
You have increased ground glass opacities or reticulations on a CT scan or decreased FVC% or DLCO% predicted value of ≥10% on pulmonary function testing.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top